Appili has assembled a leadership team with expertise in all facets of drug development, from bench to bedside.
Appili’s management team is comprised of experts in drug development, infectious disease and business development. Our collective experience spans large pharma to emerging biopharmaceutical firms, enabling us to rapidly identify promising anti-infective technologies, accelerate their development, and unlock value.
Don Cilla, PharmD, MBA
President and Chief Executive Officer
Dr. Cilla brings to Appili more than 30 years of program management experience in the drug development industry, with extensive clinical and regulatory expertise that includes direct involvement with 20 programs that became commercialized products, including Lipitor™ and Difcid™. His career includes positions in program management, drug product team leadership, clinical pharmacology, clinical development, and administration in large pharmaceutical, biotechnology, and generic drug companies. He has worked across a broad range of development positions in companies including Shire Pharmaceuticals (Takeda), MedImmune (AstraZeneca), and Otsuka America Pharmaceuticals. He also has held multiple consulting roles, outsourcing his drug development expertise to help build and lead teams for companies in need of functional area expertise. Dr. Cilla earned his Doctor of Pharmacy from the University of Michigan and an MBA from the University of Phoenix.
Yoav Golan, MD
Chief Medical Officer
Dr. Yoav Golan has an impressive 25+ year career as a medical specialist in infectious diseases. He has served as an attending physician in the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center, and as an associate professor at Tufts University School of Medicine. His extensive research in the ID space has been published in several books and over 50 peer-reviewed studies in journals, including The New England Journal of Medicine and The Lancet Infectious Diseases. His research focuses on hospital-acquired infections with emphasis on ICU infections, the impact of antibiotic resistance on outcomes, and development of early culture-independent treatment strategies. Dr. Golan’s recent work has focused on C. difficile infections as well as invasive candidiasis. He has been involved in the development of multiple anti-infectives, including, fidaxomicin, ceftaroline and bezlotuximab. He is a member of numerous medical societies, including the Infectious Disease Society of America and the American Society for Microbiology. Dr. Golan is a graduate of the Hadassah School of Medicine at the Hebrew University in Jerusalem, Israel.
Acting Chief Financial Officer
Mr. Howling has over 25 years of healthcare industry experience in senior financial positions; including 11 years with Bausch Health (formerly Biovail Corporation), as Chief Financial Officer, and Senior Vice President, Finance and Corporate Affairs; five years as Chief Financial Officer of Acerus Pharmaceuticals Corporation; and five years as Chief Financial Officer with Pharma Patch PLC. During his career, Mr. Howling has contributed to the success of multiple start-up companies, taken companies through the IPO process, and has collectively raised over US$2.5 billion in various forms of capital. Earlier in his career, Mr. Howling worked in senior financial management positions at Roberts Company Canada Limited, including roles of General Manager, Corporate Secretary and Controller, at GlaxoSmithKline (formerly Beecham Pharmaceuticals Ltd), and as an auditor with PricewaterhouseCoopers. Mr. Howling is a graduate of the ICD/Rotman Director Program and formerly a Certified Public Accountant (inactive license).